Skip to main content
Equibles
PLX logo

PLX · Protalix BioTherapeutics, Inc.

Track PLX — free

Use PLX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.64 -0.09 (-3.30%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$212.71M
Shares
80.57M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.64 Open$2.74 Day$2.62–2.75 52W close$1.67–3.15 Avg vol 30d799K Short int3.2M · 3.9% float · 4.8d Short vol64% Last earningsAug 12, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Nov 11, 2026 Est · unconfirmed · in 9 wks
Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$80.62M
Trailing 12 months
Net income (TTM)
$18.95M
Trailing 12 months
Revenue growth YoY
+27.1%
Year over year
Operating margin
28.9%
Trailing 12 months
P / E (TTM)
11.4
Trailing earnings · reciprocal yield 8.8%
FCF yield
3.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.6%
Year over year · more shares
Price change (1Y)
+61.5%
Trailing year
Short interest
3.9%
Latest settlement · 4.8 days to cover
View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 12, 2026
Q2 FY26

TL;DR. Protalix reported Q2 2026 revenues from selling goods of $19.8 million (up $4.4 million YoY) and reaffirmed full-year 2026 total revenue guidance of $78.0–$83.0 million, while swinging to $3.8 million net income and highlighting Elfabrio's U.S. patent term extension and South Korea approval.

Bullish
  • + Q2 product revenues rose $4.4 million YoY to $19.8 million driven by Elfabrio sales.
  • + Year-to-date revenue more than doubled to $53.6 million and the company achieved $22.1 million YTD net income.
  • + Q2 net income increased to $3.8 million ($0.05/share) versus $164,000 in Q2 2025.
  • + Company reaffirmed full-year 2026 revenue guidance of $78.0–$83.0 million, including the $25.0 million Chiesi milestone.
  • + Balance sheet of $40.7 million cash/short-term deposits with no debt or warrants supports operations and the PRX-115 Phase 2 trial.
Bearish
  • − Q2 cost of revenues rose 32% YoY to $7.8 million, outpacing revenue growth and pressuring gross margin.
  • − Management warned of lumpiness in Elfabrio partner purchases driven by Chiesi inventory management rather than underlying demand signals.
  • − License and R&D services revenue is set to decline materially, with the company expecting minimal such revenues going forward.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Bullish Fundamentals Weak Quant / Vol High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +17%
above
Price vs 50-day avg +9%
above
RSI (14) 59
neutral
MACD trend Positive
52-week position 66%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +12%
trailing
6-month return +23%
trailing
YTD return +47%
this year
Relative strength +6%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.93% of float · ▼ -11.5% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
101 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Weak
Revenue growth −1%
Y/Y
Gross margin 8%
expanding
EPS growth −300%
Y/Y
Free cash flow $-13.6M
Valuation P/E 11
in line
Quant / Vol
risk profile
High
Volatility 64%
annualized · 1-yr
Max drawdown −40%
past year
ATR 3.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 31, 2026
Total revenue · 2026 $78M – $83M
prior FY $52.74M midpoint +52.6% Y/Y
Fabio revenues excluding milestones · 2026 $33M – $35M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+17% Bullish
Price vs 50-day avg
+9% Bullish
RSI (14)
59 Neutral
MACD trend
Positive Bullish
52-week position
66% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +17 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.93% of float · ▼ -11.5% MoM · 4.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
101 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $3 · 66% Range high $3
vs 200-day avg +17% vs 50-day avg +9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PLX
Protalix BioTherapeutics, Inc.
this stock
$212.71M +46.7% -1.2% 11.0 3.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.64B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.46B +1.2% +20.8% 19.4 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
MRNA
Moderna, Inc.
 $57.48B +388.2% +4.3% — 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
101
% held
18.4%
Net QoQ
-2.4M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
75
View
Short & Settlement
Short Interest Falling
Shares short
3.2M
Days to cover
4.8d
Change
-411.1K sh
View
Short Volume
Short vol %
64%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
333
Value
$773
As of
Aug 4, 2026
View
Off-Exchange
Off-exchange %
49.2%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$52.7M
Net income (FY)
$-6.6M
EPS diluted
$-0.08
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 12, 2026
This year
14
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 14, 2026
Last call
Aug 12, 2026
View
Investor Relations
Latest news
Protalix BioTherapeutics to Parti…
Published
Sep 8, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
PLX +0.8% +11.9% +23.4% +2.7% +46.7%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY +1.9% +13.6% +5.5% +3.1% +34.6%
Key facts CIK 1006281 CUSIP 74365A309 13F (30d) 41 filings 41 filers Visit website Investor relations